Abstract: The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtained by the novel process has advantageous aerodynamic properties, and can be further processed to inhalable or nasally administered pharmaceutical preparations without further mechanical micronization.
Abstract: The present inventions are directed to novel aqueous compositions comprising a copolymer having water-soluble units and pendant catechols, said composition adapted for use on mammalian tissue and having a lower critical solubility temperature (LCST) of less than a physiological temperature, and their use, for example, in removing foreign particles from tissue surfaces, including ocular surfaces.
Type:
Grant
Filed:
April 16, 2014
Date of Patent:
August 23, 2016
Assignee:
California Institute of Technology
Inventors:
Hoyong Chung, Robert H. Grubbs, Daniel M. Schwartz
Abstract: Structured personal care compositions comprising a particle having an aspect ratio of greater than 1.5 are contemplated, as well as methods for using such compositions. The compositions provide a visually distinguishable, oriented pattern that is aesthetically pleasant to provide consumer appeal and product identification.
Abstract: A nutritional supplement for adults fifty years and older, and methods of use thereof, are provided that are designed to be most effective in optimizing health, improving vitality and immunity, and improving, aiding, eye and bone health.
Type:
Grant
Filed:
January 21, 2010
Date of Patent:
July 26, 2016
Assignee:
Wyeth LLC
Inventors:
Richard Cotter, Charles Mohs, Lisa Dispensa, Paula Ziegler
Abstract: The invention is directed to an intravaginal drug delivery device comprising at least one pharmaceutically active substance, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): The invention is further directed to administering one or more pharmaceutically active substances to a patient in need thereof.
Type:
Grant
Filed:
November 15, 2011
Date of Patent:
July 19, 2016
Assignees:
DSM IP ASSETS B.V., DSM BIOMEDICAL INC.
Inventors:
Robert S. Ward, Shanger Wang, Li Li, Durgaprasad Chalasani, Patrick Kiser, Meredith Roberts Clark
Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.
Type:
Grant
Filed:
June 26, 2014
Date of Patent:
July 12, 2016
Assignee:
CLS Pharmaceuticals, Inc.
Inventors:
C. Michael Samson, Bo Liang, Joseph A. Capriotti
Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].
Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.
Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
July 5, 2016
Assignee:
SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
Abstract: The present invention relates to compounds derived from steroids of the general formula (I) wherein L represents a linker and R# represents a steroid residue, the use of compounds of the general formula (I) in medicine and for the prophylaxis and/or the treatment of infectious diseases. Furthermore described are pharmaceutical compositions containing at least one compound of the general formula (I). A further aspect of the invention relates to the synthesis of said compounds of the general formula (I).
Type:
Grant
Filed:
October 6, 2011
Date of Patent:
July 5, 2016
Assignee:
Justus-Liebig-Universitat Giessen
Inventors:
Katja Becker, Reimar Krieg, Bruno Schönecker
Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Type:
Grant
Filed:
October 16, 2013
Date of Patent:
July 5, 2016
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
Abstract: Microbial growth inhibiting solutions and methods of employing the microbial growth inhibiting solutions in flushing and coating medical devices are disclosed. In alternative embodiments, the microbial growth inhibiting solutions include combinations of a chelating agent with a C4-C9 carboxylate antimicrobial agent, for example, such as n-octanoic acid. Methods of using these microbial growth inhibiting solutions for coating a medical device and for inhibiting catheter infection are also disclosed.
Type:
Grant
Filed:
April 28, 2015
Date of Patent:
July 5, 2016
Inventors:
Stanley L. Mills, Jacqueline L. Mills, Robert D. Maurer, Gary L. Rayburn, Marvin A. Cuchens
Abstract: A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.
Type:
Grant
Filed:
July 19, 2011
Date of Patent:
June 28, 2016
Assignee:
3M INNOVATIVE PROPERTIES COMPANY
Inventors:
James P. DiZio, Elizabeth E. Johnson, Zheng Zhi Wu, Amy Preszier Prince
Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one transition metal salt and least one proteinaceous material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one transition metal salt and the at least one proteinaceous material.
Type:
Grant
Filed:
June 5, 2014
Date of Patent:
June 28, 2016
Assignee:
Dow AgroSciences LLC
Inventors:
Stephen L. Wilson, Lei Liu, James D. Thomas, Raymond E. Boucher, Jr., James E. Dripps, Margaret S. Kempe
Abstract: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SURI and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.
Type:
Grant
Filed:
September 27, 2013
Date of Patent:
June 28, 2016
Assignees:
University of Maryland, Baltimore, The United States of America as Represented by the Dept. of Veterans Affairs
Abstract: Topical cosmetic compositions are provided that can comprise a Phyllanthus extract, a Bellis extract, and a licorice (Glycyrrhiza) extract. These compositions are used for topical cosmetic applications, particularly to lighten skin. Methods for lightening skin are also provided and can comprise topically administering a therapeutically effective amount of a topical cosmetic composition comprising a Phyllanthus extract, a Bellis extract, and a licorice extract, to skin of a subject in need thereof.
Type:
Grant
Filed:
November 24, 2015
Date of Patent:
June 14, 2016
Assignee:
Stiefel Laboratories, Inc.
Inventors:
Joao Paulo Caetano, Monica Alves Mariani De Oliveira
Abstract: Compositions for providing hair care benefits, such as smoothing, anti-static control, color protection, frizz control and moisturization are disclosed. The compositions maintain clarity, show no separation upon standing, and remain flowable liquids at room temperature. The compositions comprise a premix consisting essentially of (a) siloxane polymers containing one or more functional groups selected from amino, phenyl, methoxy, hydroxyl, fatty alcohol, fatty acid, alkyl and combinations thereof; and (b) materials selected from dimethicones having a viscosity of from about 20 to about 10,000 centipoise, mono-esters containing 20 or fewer carbon atoms, ethers containing 20 or fewer carbon atoms, linear or branched hydrocarbons containing 12 to 20 carbon atoms, and combinations thereof. The compositions can be applied directly to hair (i.e., “neat”) or via conventional hair treatment compositions, such as shampoos or conditioners.
Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
Type:
Grant
Filed:
October 3, 2014
Date of Patent:
May 31, 2016
Assignee:
ALTRIA CLIENT SERVICES LLC
Inventors:
Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke